In line with this and with our previous studies, one could imagine a combination therapy of NRP-dependent tumor cell and NRP2 dependent macrophage blockade in combination with conventional chemotherapy or ICI that might result in a significantly improved outcome in the treatment of advanced or metastasized PDAC. The gene discussed is NRP2; the disease is neoplasm.